Prospective study of the potentiation of acenocoumarol by amiodarone.
The influence of oral amiodarone on the anticoagulant effect of the coumarin derivative acenocoumarol has been investigated prospectively in 10 patients with normal renal, hepatic and haematological function and who were not in cardiac failure. The daily dose of acenocoumarol was sufficient to produce a prothrombin activity of 25 to 35%. When the prothrombin time had become stable amiodarone 600 mg/d was administered for 1 week followed by 400 mg/d for the next 3 weeks. A decrease in prothrombin activity from 30.5 to 20.2% was observed, associated with a decrease in vitamin K coagulation factors, after a mean of 4 days following commencement of amiodarone. In 6 patients a prothrombin activity less than 20% required a 60% reduction in the dose of acenocoumarol after 1 week of amiodarone 600 mg, and a 33% reduction after 3 weeks of amiodarone 400 mg. There was no correlation between the plasma amiodarone and the decrease in prothrombin activity. Inhibition of acenocoumarol metabolism by amiodarone is the most likely explanation of these findings.
D000074:Acenocoumarol / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000097:blood / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D001777:Blood Coagulation / Q000187:drug effects*; D004357:Drug Synergism; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011517:Prothrombin Time
D001572:Benzofurans; D000074:Acenocoumarol; D000638:Amiodarone